Literature DB >> 21519907

Motor symptoms of schizophrenia: is tardive dyskinesia a symptom or side effect? A modern treatment.

Vladimir Lerner1, Chanoch Miodownik.   

Abstract

Abnormal involuntary dyskinetic movements in schizophrenia patients have been documented for more than 140 years. Clinicians should distinguish between two kinds of disturbances-spontaneous dyskinetic movements and movements induced by psychotropic medications-which may look familiar clinically. As a modern term, tardive dyskinesia (TD) is a potentially permanent neurological hyperkinetic movement disorder that occurs after months or years of taking psychotropic drugs. Several distinct forms of TD exist, specifically tardive akathisia, tardive blepharospasm, tardive dystonia, tardive gait, tardive myoclonus, tardive tremor, and tardive tics, and they have different pathophysiologies and treatment. The pathogenesis of TD remains unclear, and the pathophysiology is complex and multifactorial. Moreover, there is solid evidence of a genetic predisposition to TD. This article summarizes recent relevant publications concerning TD and the most recent studies regarding treatment of this disorder with antioxidative agents.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21519907     DOI: 10.1007/s11920-011-0202-6

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  82 in total

1.  Venlafaxine and tardive blepharospasm: a case report.

Authors:  Yu Lee; Wei-Chiang Yeh; Mian-Yoon Chong; Pao-Yen Lin; Yung-Yee Chang
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-03-30       Impact factor: 5.067

2.  Protein kinase inhibition by omega-3 fatty acids.

Authors:  B Mirnikjoo; S E Brown; H F Kim; L B Marangell; J D Sweatt; E J Weeber
Journal:  J Biol Chem       Date:  2001-01-10       Impact factor: 5.157

Review 3.  Tardive dyskinesia and essential fatty acids.

Authors:  Krishna Vaddadi; Kerstin Hakansson; Jerry Clifford; John Waddington
Journal:  Int Rev Psychiatry       Date:  2006-04

Review 4.  Levetiracetam in brain ischemia: clinical implications in neuroprotection and prevention of post-stroke epilepsy.

Authors:  Vincenzo Belcastro; Laura Pierguidi; Nicola Tambasco
Journal:  Brain Dev       Date:  2010-07-13       Impact factor: 1.961

5.  Vitamin E (alpha-tocopherol) in the treatment of tardive dyskinesia: a statistical meta-analysis.

Authors:  Y Barak; M Swartz; E Shamir; D Stein; A Weizman
Journal:  Ann Clin Psychiatry       Date:  1998-09       Impact factor: 1.567

6.  Association analysis of polymorphisms in the N-methyl-D-aspartate (NMDA) receptor subunit 2B (GRIN2B) gene and tardive dyskinesia in schizophrenia.

Authors:  Ying-Jay Liou; Ying-Chieh Wang; Jen-Yeu Chen; Ya-Mei Bai; Chao-Cheng Lin; Ding-Lieh Liao; Tzu-Ting Chen; Mao-Liang Chen; Geng-Han Mo; I-Ching Lai
Journal:  Psychiatry Res       Date:  2007-07-31       Impact factor: 3.222

7.  A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia.

Authors:  J B Lohr; M P Caligiuri
Journal:  J Clin Psychiatry       Date:  1996-04       Impact factor: 4.384

8.  Potential role of dietary omega-3 essential fatty acids on some oxidant/antioxidant parameters in rats' corpus striatum.

Authors:  Mustafa Sarsilmaz; Ahmet Songur; Hüseyin Ozyurt; Ilter Kuş; Oğuz Aslan Ozen; Birsen Ozyurt; Sadik Söğüt; Omer Akyol
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2003-10       Impact factor: 4.006

9.  Abnormal involuntary movements in schizophrenia: are they related to the disease process or its treatment? Are they associated with changes in dopamine receptors?

Authors:  T J Crow; A J Cross; E C Johnstone; F Owen; D G Owens; J L Waddington
Journal:  J Clin Psychopharmacol       Date:  1982-10       Impact factor: 3.153

Review 10.  Pharmacogenetics of antipsychotic-induced side effects.

Authors:  Todd Lencz; Anil K Malhotra
Journal:  Dialogues Clin Neurosci       Date:  2009       Impact factor: 5.986

View more
  10 in total

1.  Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.

Authors:  Christoph U Correll; Johan Detraux; Jan De Lepeleire; Marc De Hert
Journal:  World Psychiatry       Date:  2015-06       Impact factor: 49.548

2.  Repetitive transcranial magnetic stimulation for treatment of tardive syndromes: double randomized clinical trial.

Authors:  Eman M Khedr; Bastawy Al Fawal; Ahmed Abdelwarith; Mostafa Saber; John C Rothwell
Journal:  J Neural Transm (Vienna)       Date:  2018-10-13       Impact factor: 3.575

3.  Tardive Blepharospasm and Meige Syndrome during Treatment with Quetiapine and Olanzapine.

Authors:  Ayça Kiliç; Evrim Erten; Armağan Özdemir
Journal:  Noro Psikiyatr Ars       Date:  2015-06-01       Impact factor: 1.339

Review 4.  Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects.

Authors:  George Anderson; Michael Maes
Journal:  Metab Brain Dis       Date:  2012-04-25       Impact factor: 3.584

5.  Nigella sativa Oil Reduces Extrapyramidal Symptoms (EPS)-Like Behavior in Haloperidol-Treated Rats.

Authors:  Tafheem Malik; Sheema Hasan; Shahid Pervez; Tasneem Fatima; Darakhshan Jabeen Haleem
Journal:  Neurochem Res       Date:  2016-10-18       Impact factor: 3.996

Review 6.  Therapeutic Perspective on Tardive Syndrome with Special Reference to Deep Brain Stimulation.

Authors:  Ryoma Morigaki; Hideo Mure; Ryuji Kaji; Shinji Nagahiro; Satoshi Goto
Journal:  Front Psychiatry       Date:  2016-12-26       Impact factor: 4.157

7.  Manual Dexterity in Schizophrenia-A Neglected Clinical Marker?

Authors:  Maxime Térémetz; Loïc Carment; Lindsay Brénugat-Herne; Marta Croca; Jean-Pierre Bleton; Marie-Odile Krebs; Marc A Maier; Isabelle Amado; Påvel G Lindberg
Journal:  Front Psychiatry       Date:  2017-07-10       Impact factor: 4.157

8.  The critical balance between dopamine D2 receptor and RGS for the sensitive detection of a transient decay in dopamine signal.

Authors:  Hidetoshi Urakubo; Sho Yagishita; Haruo Kasai; Yoshiyuki Kubota; Shin Ishii
Journal:  PLoS Comput Biol       Date:  2021-09-30       Impact factor: 4.475

9.  Long-Term Follow-Up of 12 Patients Treated with Bilateral Pallidal Stimulation for Tardive Dystonia.

Authors:  Hiroshi Koyama; Hideo Mure; Ryoma Morigaki; Ryosuke Miyamoto; Kazuhisa Miyake; Taku Matsuda; Koji Fujita; Yuishin Izumi; Ryuji Kaji; Satoshi Goto; Yasushi Takagi
Journal:  Life (Basel)       Date:  2021-05-24

Review 10.  New and emerging treatments for symptomatic tardive dyskinesia.

Authors:  Abdul Qayyum Rana; Zishan M Chaudry; Pierre J Blanchet
Journal:  Drug Des Devel Ther       Date:  2013-11-06       Impact factor: 4.162

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.